Home › Atherosclerosis › New Jersey
Pag-aaral pangklinika para sa Atherosclerosis sa New Jersey
6 pag-aaral para sa Atherosclerosis ang naghahanap ng mga kalahok sa mga site sa New Jersey.
Mga Lungsod sa New Jersey
Opisyal na teksto ng pag-aaral (English)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- Clinical Research of Philadelphia, Pennington
- Cardio Metabolic Institute, Somerset
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07157774Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- CardioMetabolic Collaborative Clinic, Somerset
Nagre-recruitPhase 3
Edad 45 hanggang 99 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07037433Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Hypertension & Nephrology Association, Eatontown
- New Jersey Kidney Care, Jersey City
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Bridgewater
- Research Site, Elmer
- Research Site, Haddon Heights
- at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT07000357Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Overlook Medical Center, Summit
Nagre-recruitPhase 3
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06813911Pelacarsen Roll-over Extension Program
- Robert Wood Johnson Medical School, New Brunswick
- Overlook Medical Center, Summit
Nagre-recruitPhase 3
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT06875973Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.